Search results
Biomarin exec sells over $3 million in company stock By Investing.com
Investing.com· 6 days agoGeorge Eric Davis, the Executive Vice President and Chief Legal Officer of Biomarin Pharmaceutical...
Biomarin Pharmaceutical Inc TradeGate Stock Price Today | NASDAQ BMRN Live Ticker - Investing.com
Investing.com· 2 hours agoRisk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for ...
BioMarin CFO sells $375,950 in stock, buys shares worth $315,500 By Investing.com
Investing.com· 5 days agoBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported a series of transactions by its Executive Vice...
Analysts review Biomarin Pharmaceutical Inc.’s rating – Knox Daily
Knox Daily· 1 day agoIn a filing, Biomarin Pharmaceutical Inc. revealed its EVP, Chief Financial Officer Mueller Brian unloaded Company’s shares for reported $0.38 million on May 30 ’24. In the ...
Insider Selling: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) EVP Sells $3,043,733.50 in Stock
ETF DAILY NEWS· 4 days agoBioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) EVP George Eric Davis sold 40,850 shares of the business’s stock in a transaction on Tuesday, May 28th. The shares ...
BridgeBio posts BioMarin-beating data on dwarfism drug prospect
FierceBiotech· 2 days agoBridgeBio Pharma has bounced back from the withdrawal of infigratinib in oncology, linking the...
BridgeBio Stock Gives Up Gains On Comparisons To BioMarin Drug
Investor's Business Daily· 2 days agoShares undercut their 50-day line. At the close on the stock market today, BridgeBio stock skidded...
June's Biotech Boom: 3 Stocks to Buy for a Summertime Surge
InvestorPlace· 23 hours agoBiotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the...
BridgeBio data show sustained benefit for achondroplasia drug
BioPharma Dive via Yahoo Finance· 2 days agoLonger follow-up results from a mid-stage trial indicate the company’s treatment for a genetic cause...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio...
Morningstar· 15 hours agoNEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. (“BridgeBio” or the “Company”) (NASDAQ: BBIO). Such investors ...